Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Innocrin Pharmaceuticals

Innocrin Pharmaceuticals
Accelerator/Inc LATEST DEAL TYPE

Developer of oral inhibitors designed to treat advanced breast and prostate cancer. The company's oral inhibitors consists of oral CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially in other hormonally-driven conditions such as breast cancer, endometriosis or congenital adrenal hyperlplasia.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Primary Office
  • 4505 Emperor Boulevard
  • Suite 315
  • Durham, NC 27703
  • United States

+1 (919) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Innocrin Pharmaceuticals’s full profile, request a free trial.

Innocrin Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 0000 Completed Generating Revenue
1. Later Stage VC (Series D) 14-Apr-2015 0000 0000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Innocrin Pharmaceuticals Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
A&B Equity Holdings Other Minority 000 0000 000000 0
Astellas Venture Management Corporate Venture Capital Minority 000 0000 000000 0
Eshelman Ventures Venture Capital Minority 000 0000 000000 0
Hatteras Venture Partners Venture Capital Minority 000 0000 000000 0
Intersouth Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Innocrin Pharmaceuticals Executive Team (7)

Name Title Board
Charles Osborne Jr. Chief Financial Officer & Corporate Secretary
Joel Eisner Ph.D Vice President, Clinical Operations
Ronald Fleming Vice President, Translational Research
Edwina Baskin-Bey MD Chief Medical Officer
Fred Eshelman Chief Executive Officer & Board Member

2 Former Executives

You’re viewing 5 of 7 executives. Get the full list »

Innocrin Pharmaceuticals Board Members (10)

Name Representing Role Since Contact
Andrew von Eschenbach MD Self Board Member 000 0000
Douglas Reed MD Hatteras Venture Partners Chairman 000 0000
Fred Eshelman Self Chief Executive Officer & Board Member 000 0000
Kristopher Wood Lurie Holdings Board Member 000 0000
Richard Kent MD Intersouth Partners Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »